These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 35195401)
21. Ligands for the investigation of 5-HT autoreceptor function. Roberts C; Price GW; Middlemiss DN Brain Res Bull; 2001 Nov; 56(5):463-9. PubMed ID: 11750791 [TBL] [Abstract][Full Text] [Related]
22. Role of 5-HT5A receptors in the consolidation of memory. Gonzalez R; Chávez-Pascacio K; Meneses A Behav Brain Res; 2013 Sep; 252():246-51. PubMed ID: 23735322 [TBL] [Abstract][Full Text] [Related]
23. Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry. Corbett DF; Heightman TD; Moss SF; Bromidge SM; Coggon SA; Longley MJ; Roa AM; Williams JA; Thomas DR Bioorg Med Chem Lett; 2005 Sep; 15(18):4014-8. PubMed ID: 16002289 [TBL] [Abstract][Full Text] [Related]
24. Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. Dukat M; Mosier PD; Kolanos R; Roth BL; Glennon RA J Med Chem; 2008 Feb; 51(3):603-11. PubMed ID: 18201064 [TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships of serotonin 5-HT Thirumaran SL; Lepailleur A; Rochais C Eur J Med Chem; 2019 Dec; 183():111705. PubMed ID: 31581003 [TBL] [Abstract][Full Text] [Related]
26. Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats. Popik P; Krawczyk M; Kuziak A; Bugno R; Hogendorf A; Staroń J; Nikiforuk A J Psychopharmacol; 2019 Nov; 33(11):1447-1455. PubMed ID: 31452444 [TBL] [Abstract][Full Text] [Related]
27. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. De Ponti F; Tonini M Drugs; 2001; 61(3):317-32. PubMed ID: 11293643 [TBL] [Abstract][Full Text] [Related]
28. The 5-HT5A receptor regulates excitability in the auditory startle circuit: functional implications for sensorimotor gating. Curtin PC; Medan V; Neumeister H; Bronson DR; Preuss T J Neurosci; 2013 Jun; 33(24):10011-20. PubMed ID: 23761896 [TBL] [Abstract][Full Text] [Related]
29. A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. Harsing LG; Prauda I; Barkoczy J; Matyus P; Juranyi Z Neurochem Res; 2004 Aug; 29(8):1487-97. PubMed ID: 15260125 [TBL] [Abstract][Full Text] [Related]
30. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression. Kassai F; Schlumberger C; Kedves R; Pietraszek M; Jatzke C; Lendvai B; Gyertyán I; Danysz W Behav Pharmacol; 2012 Aug; 23(4):397-406. PubMed ID: 22785385 [TBL] [Abstract][Full Text] [Related]
31. Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential. Volk B; Nagy BJ; Vas S; Kostyalik D; Simig G; Bagdy G Curr Top Med Chem; 2010; 10(5):554-78. PubMed ID: 20166946 [TBL] [Abstract][Full Text] [Related]
32. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. Brea J; Rodrigo J; Carrieri A; Sanz F; Cadavid MI; Enguix MJ; Villazón M; Mengod G; Caro Y; Masaguer CF; Raviña E; Centeno NB; Carotti A; Loza MI J Med Chem; 2002 Jan; 45(1):54-71. PubMed ID: 11754579 [TBL] [Abstract][Full Text] [Related]
33. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia. Yamazaki M; Harada K; Yamamoto N; Yarimizu J; Okabe M; Shimada T; Ni K; Matsuoka N Eur Neuropsychopharmacol; 2014 Oct; 24(10):1698-708. PubMed ID: 25108314 [TBL] [Abstract][Full Text] [Related]
35. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Slassi A Curr Top Med Chem; 2002 Jun; 2(6):559-74. PubMed ID: 12052194 [TBL] [Abstract][Full Text] [Related]